{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:38:34Z","timestamp":1787319514286,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infections and sepsis are the leading causes of death in intensive care units (ICUs). Antimicrobial agent selection is challenging because the intervention is directly related to the outcome, and the problem of antimicrobial resistance (AMR) must be considered. Therefore, in this study, we aimed to clarify the epidemiological data and examine whether the detection rate of multidrug-resistant (MDR) bacteria differed depending on the presence or absence of the risk of MDR bacterial infections to establish guidance regarding the choice of antimicrobial therapy for ICU patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective case\u2012control study was performed in a single ICU in Japan. Patients admitted to the ICU who underwent blood culture (BC) analysis were considered for inclusion in this study; patients were at risk of MDR bacterial infections, and controls were not. The primary outcome measure was the detection rate of MDR bacteria in BCs collected from patients and controls. The secondary outcome measure was the selection rate of anti-\n                      <jats:italic>Pseudomonas<\/jats:italic>\n                      and anti-methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) drugs for patients and controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 1,730 patients admitted to the ICU during the study period, BCs were obtained from 186 patients, and 173 samples were finally included in the analysis (n\u2009=\u2009129 cases; n\u2009=\u200944 controls). No MDR bacteria or\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      were detected in the controls (14 (11%) vs. 0 (0%)) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014) However, there was no difference in empiric antimicrobials, including anti-MRSA (30 (23%) vs. 12 (27%)) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.592) and anti-\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (61 (47%) vs. 16 (36%)) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.208) drugs, that were administered to the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even in critically ill patients in the ICU, MDR bacteria are unlikely to be detected in patients without the risk of MDR bacterial infections. Therefore, for such patients, a strategy of starting empiric narrow-spectrum antimicrobial therapy rather than empiric broad-spectrum therapy should be considered. This strategy, in conjunction with daily updates of clinical and epidemiological data at each facility, will promote the appropriate use of antimicrobials and reduce the emergence of MDR bacteria in the ICU.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : None.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-023-01303-2","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T21:01:59Z","timestamp":1694466119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Empiric antimicrobial therapy in the intensive care unit based on the risk of multidrug-resistant bacterial infection: a single-centre case\u2012control study of blood culture results in Japan"],"prefix":"10.1186","volume":"12","author":[{"given":"Taikan","family":"Nanao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0891-5520(05)70366-4","volume":"11","author":"SK Fridkin","year":"1997","unstructured":"Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am. 1997;11:479\u201396.","journal-title":"Infect Dis Clin North Am"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323\u20139.","journal-title":"JAMA"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"JL Vincent","year":"2020","unstructured":"Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323:1478\u201387.","journal-title":"JAMA"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","volume":"38","author":"A Tabah","year":"2012","unstructured":"Tabah A, Koulenti D, Laupland K, Misset B, Valles J, De Carvalho FB, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study. Intensive Care Med. 2012;38:1930\u201345.","journal-title":"Intensive Care Med"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","volume":"54","author":"M Paul","year":"2010","unstructured":"Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/jhm.899","volume":"6","author":"ST Micek","year":"2011","unstructured":"Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. J Hosp Med. 2011;6:405\u201310.","journal-title":"J Hosp Med"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhin.2006.04.015","volume":"64","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64:7\u201315.","journal-title":"J Hosp Infect"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","volume":"3","author":"C Rhee","year":"2020","unstructured":"Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open. 2020;3:e202899.","journal-title":"JAMA Netw Open"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247.","journal-title":"Intensive Care Med"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1002\/ams2.659","volume":"8","author":"M Egi","year":"2021","unstructured":"Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). Acute Med Surg. 2021;8:e659.","journal-title":"Acute Med Surg"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(17)30724-7","volume":"18","author":"M Sharland","year":"2018","unstructured":"Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, et al. Classifying antibiotics in the WHO essential medicines list for optimal use-be AWaRe. Lancet Infect Dis. 2018;18:18\u201320.","journal-title":"Lancet Infect Dis"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/cid\/ciw425","volume":"63","author":"KE Goodman","year":"2016","unstructured":"Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum \u03b2-lactamase-producing organism. Clin Infect Dis. 2016;63:896\u2013903.","journal-title":"Clin Infect Dis"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/cid\/civ121","volume":"60","author":"WC Rottier","year":"2015","unstructured":"Rottier WC, Bamberg YR, Dorigo-Zetsma JW, Van Der Linden PD, Ammerlaan HS, Bonten MJ. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis. Clin Infect Dis. 2015;60:1622\u201330.","journal-title":"Clin Infect Dis"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/JCM.06002-11","volume":"50","author":"CI Kang","year":"2012","unstructured":"Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012;50:312\u20137.","journal-title":"J Clin Microbiol"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1086\/596709","volume":"48","author":"V Schechner","year":"2009","unstructured":"Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis. 2009;48:580\u20136.","journal-title":"Clin Infect Dis"},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00003246-199905000-00020","volume":"27","author":"MJ Richards","year":"1999","unstructured":"Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National nosocomial infections surveillance system. Crit Care Med. 1999;27:887\u201392.","journal-title":"Crit Care Med."},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2019.296","volume":"41","author":"LM Weiner-Lastinger","year":"2020","unstructured":"Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the national healthcare safety network, 2015\u20132017. Infect Control Hosp Epidemiol. 2020;41:1\u201318.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13756-022-01146-3","volume":"11","author":"H Yoshida","year":"2022","unstructured":"Yoshida H, Motohashi T, De Bus L, De Waele J, Takaba A, Kuriyama A, et al. Use of broad-spectrum antimicrobials for more than 72 h and the detection of multidrug-resistant bacteria in Japanese intensive care units: a multicenter retrospective cohort study. Antimicrob Resist Infect Control. 2022;11:119.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00134-020-06111-5","volume":"46","author":"L De Bus","year":"2020","unstructured":"De Bus L, Depuydt P, Steen J, Dhaese S, De Smet K, Tabah A, et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Med. 2020;46:1404\u201317.","journal-title":"Intensive Care Med"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1213\/ANE.0000000000004072","volume":"129","author":"MJG Sigakis","year":"2019","unstructured":"Sigakis MJG, Jewell E, Maile MD, Cinti SK, Bateman BT, Engoren M. Culture-negative and culture-positive sepsis: a comparison of characteristics and outcomes. Anesth Analg. 2019;129:1300\u20139.","journal-title":"Anesth Analg"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-023-01303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-023-01303-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-023-01303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:40:55Z","timestamp":1700376055000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-023-01303-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1186\/s13756-023-01303-2","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional approval was obtained from the Yokohama Rosai Hospital Ethics Committee (approval number 2021-18). Informed consent was obtained in an opt-out format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}